You are here: Home: CCU 2 | 2004: Faculty disclosures
FACULTY DISCLOSURES
As a provider accredited by the ACCME, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
|
Richard M Goldberg, MD |
Grants/Research Support: Pfizer Inc, Roche Laboratories Inc, Sanofi-Synthelabo Inc
Consultant: Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Synthelabo Inc Stock Shareholder: Bristol-Myers Squibb Company Honorarium: Eli Lilly & Company, Pfizer Inc, Roche Laboratories Inc, Sanofi-Synthelabo Inc |
Axel Grothey, MD |
Grants/Research Support: Aventis Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi-Synthelabo Inc, Consultant: Sanofi-Synthelabo Inc
Honorarium: Aventis Pharmaceuticals Inc, Bristol-Myers Squibb Company, Roche Laboratories Inc, Sanofi-Synthelabo Inc |
Heinz-Josef Lenz, MD, FACP |
Consultant: Bristol-Myers Squibb Company, Chiron Corporation, Eli Lilly & Company, Genentech BioOncology, Pfizer Inc, Response Genetics Inc, Roche Laboratories Inc, Sanofi-Synthelabo Inc Honorarium: Aventis Pharmaceuticals Inc, Bristol-Myers Squibb Company, Chiron Corporation, Eli Lilly & Company, Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Synthelabo Inc |
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the FDA. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
|